Naperville, ILNCT06783335Now EnrollingIRB Ready

Heart Failure NYHA Class III Clinical Trial in Naperville, IL

Access cutting-edge heart failure nyha class iii treatment through this clinical trial at a research site in Naperville. Study-provided care at no cost to qualified participants.

Sponsored by Endotronix, Inc.

Quick Self-Assessment

See if you qualify for this Naperville location

Preparing your pre-screening questions…

Expert Care in Naperville

Access heart failure nyha class iii specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart failure nyha class iii treatment provided free

Apply for This Naperville Location

Check if you qualify for this heart failure nyha class iii clinical trial in Naperville, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Naperville

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Naperville site if eligible
  4. 4Begin participation

About This Heart Failure NYHA Class III Study in Naperville

This retrospective, non-randomized cohort study will evaluate how well the Cordella PA Sensor System works compared to standard medication treatment in people with chronic heart failure. The study will track patients for two years to see if those using the Cordella system have fewer deaths and hospitalizations related to heart failure.

Sponsor: Endotronix, Inc.

Who Can Participate

Inclusion Criteria

for Cordella PA Sensor System Cohort:
Received Cordella PA Sensor System implant between 10/1/2024-12/31/2029
Documented chronic heart failure with NYHA Class III symptoms
On guideline-directed medical therapy based on ejection fraction status:
For reduced EF (≤40%): At least one fill of ACE/ARB/ARNI, MRA, BB, or SGLT2i, and one fill of a loop diuretic
For preserved EF (\>40%): At least one fill of a loop diuretic
Has continuous health insurance enrollment for 12 months prior to implant Inclusion Criteria for Standard of Care Control Cohort:
Two or more encounters with diagnosis codes for chronic systolic and/or diastolic heart failure
Documented ejection fraction reading within 6 months (+ or -) of second heart failure encounter
On guideline-directed medical therapy based on ejection fraction status:
For reduced EF (≤40%): At least one fill of ACE/ARB/ARNI, MRA, BB, or SGLT2i, and one fill of a loop diuretic
For preserved EF (\>40%): At least one fill of a loop diuretic
Has continuous health insurance enrollment for 12 months prior to study entry

Exclusion Criteria

No implanted pulmonary artery sensor or monitoring at any time (Standard of Care Control Cohort only)
Record of temporary mechanical circulatory support during baseline period
Diagnosis of cardiogenic shock during baseline period
Receiving palliative care/hospice during baseline period
Record of end-stage renal disease during baseline period
Unable to take dual antiplatelet therapy or anticoagulants for one month post implant (Cordella Cohort only)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Naperville?

Yes, this clinical trial (NCT06783335) has an active research site in Naperville, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure NYHA Class III Treatment Options in Naperville, IL

If you're searching for heart failure nyha class iii treatment options in Naperville, IL, this clinical trial (NCT06783335) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Naperville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart failure nyha class iii specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure nyha class iii clinical trials near you to find additional studies recruiting in your area.

More Heart Failure Trials in Naperville, IL

See all heart failure clinical trials recruiting in Naperville — not just this study.

Browse Heart Failure Trials in Naperville →

Browse More Trials by Condition

Heart Failure TrialsAnkylosing Spondylitis TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Naperville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Naperville, IL